A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

Antonio E. Muruato,Camila R. Fontes-Garfias,Ping Ren,Mariano A. Garcia-Blanco,Vineet D. Menachery,Xuping Xie,Pei-Yong Shi
DOI: https://doi.org/10.1038/s41467-020-17892-0
IF: 16.6
2020-08-13
Nature Communications
Abstract:Abstract Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.
multidisciplinary sciences
What problem does this paper attempt to address?
The problem that this paper attempts to solve is that in COVID - 19 diagnosis, convalescent plasma therapy and vaccine development, there is an urgent need for a high - throughput method to measure SARS - CoV - 2 neutralizing antibodies. Specifically, the paper introduced a fluorescence - based SARS - CoV - 2 neutralizing antibody detection method. This method can quickly and accurately detect neutralizing antibodies in COVID - 19 patient samples, and its results are comparable to those of the traditional plaque - reduction neutralization test (PRNT), which is the gold - standard test. In addition, this method is specific and does not cross - react with patient samples infected with other viruses, bacteria or parasites. Therefore, this study provides a rapid platform that can be expanded for screening the population for COVID - 19 antibody protection, which is crucial for safely restarting the community.